Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27817512 | 0.89 | HPGD (0.52) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| SCHEMBL12205709 | 0.85 | KMT2A (0.56) | ALDH1A1SMN1; SMN2HPGDHSD17B10HDAC8 | |
| SCHEMBL29772431 | 0.84 | MLYCD (0.58) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| SCHEMBL155518 | 0.84 | MLYCD (0.58) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| SCHEMBL9783640 | 0.84 | HDAC1 (0.60) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| SCHEMBL24998749 | 0.84 | MLYCD (0.58) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| SCHEMBL13495008 | 0.83 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| SCHEMBL14828665 | 0.83 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| Hydrochloric Acid SCHEMBL7849680 | 0.83 | MLYCD (0.56) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 | |
| SCHEMBL2446701 | 0.83 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2HPGDRAB9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103000-A1 | PREPARATION METHOD FOR N-ALKENYL AMIDE | 中国石油化工股份有限公司 | 2025-05-22 | — | — | WO | claimed |
| CN-120020117-A | Process for the preparation of N-vinylamides | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | claimed |
| WO-2025103000-A1 | PREPARATION METHOD FOR N-ALKENYL AMIDE | 中国石油化工股份有限公司 | 2025-05-22 | — | — | WO | disclosed |
| CN-120020117-A | Process for the preparation of N-vinylamides | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-106543058-B | A kind of chirality selenium carbamide compounds and its preparation and application | 中国科学院福建物质结构研究所 | 2019-09-20 | — | — | CN | disclosed |
| US-8049037-B2 | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | ALLERGAN, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2000055179-A1 | NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-6121437-A | SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1995024883-A1 | COMPOSITIONS FOR RETARDING AND PREVENTING HAIR LOSS | LADRON DE CEGAMA ANGEL (ES) | 1995-09-21 | — | — | WO | disclosed |
| EP-0522606-A2 | Pyridine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | S1PR1, S1PR2, S1PR3 | ALDH1A1 2830/4885SMN1; SMN2 1727/4885HPGD 2890/4885 |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | ALDH1A1 4612/4885SMN1; SMN2 1704/4885HPGD 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.